Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fingolimod effects on cytokines in RRMS
NCT02373098Phase 4Completed
- Sponsor
- Novartis
- Start
- Mar 2015
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of fingolimod in relapsing-remitting multiple sclerosis (RRMS), sponsored by Novartis. Started Mar 2015; status: completed.
02
Drugs
fingolimod
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT02373098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02373098.